12 publications
Name | Date | Type | Actions |
---|---|---|---|
Mis en oeuvre des recommandations AFEP/MEDEF du 6 octobre 2008 sur les rémunérations des dirigeants mandataires sociaux des sociétés cotées Lors de sa réunion du 5 décembre 2008, le Conseil d’administration a pris connaissance des recommandations AFEP-MEDEF du 8 octobre 2008 sur la rémunération des dirigeants sociaux des sociétés cotées. |
Public releases | ||
Vétoquinol strengthens its position in Europe with the acquisition of Ascor Chimici in Italy Vétoquinol announces the signing of a contract to acquire 100 percent of the shares of Ascor Chimici S.r.l, which will take effect on 1 December 2008. |
Public releases | ||
Revenues for the first nine months of 2008 Revenues increased by 3.1% during the first 9 months of 2008 to 171.2 million euros (4.8% on a like-for-like basis). |
Public releases | ||
Vétoquinol: 2008 results expected to be in line with objectives At its meeting of 25 August 2008, the Board of Directors of Vétoquinol S.A. reviewed the Group’s operations and approved the financial statements for |
Public releases | ||
2008 Interim Revenues increase by 5% Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros |
Public releases | ||
Pierre Konareff est nommé Directeur Financier et Juridique du Groupe Vétoquinol (french) Vétoquinol annonce la nomination de Pierre Konareff au poste de Directeur Financier et Juridique du groupe. |
Public releases | ||
Vétoquinol strengthens its presence in Canada in the compagnion animal market Vétoquinol announces the acquisition of the animal health business assets of VETCOM 1979 INC. The animal health business of VETCOM 1979 INC. includes annual revenue of around CAD1.5 million. The company covers nearly 65% of the market for ophthalmological unguents in Canada. |
Public releases | ||
Satisfactory revenue growth for 1st quarter 2008: +4.6% on a constant basis Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment. |
Public releases | ||
Earnings for 2007 attest to strength of business growth model The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance |
Public releases | ||
VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe |
Public releases |